VigiLanz has launched a new solution to enable researchers to identify more eligible subjects for enrolment in clinical trials accurately and in near real time.

The new VigiLanz Research solution will help clinical trial sites that seek to expedite recruitment by automating the identification process of patients.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will also help the sites obtain insights on patients screened for eligibility and meet time-sensitive enrolment targets.

VigiLanz CEO Dr David Goldsteen said: “VigiLanz Research is streamlining the clinical trial recruitment process.

“This new solution leverages our two decades of clinical surveillance expertise into a system that empowers researchers to screen more qualified candidates.

“For hospitals, this increases the likelihood for clinical trial success, and for sponsors, this potentially saves millions of dollars and helps get products to market faster.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

VigiLanz Research will also help clinical staff and hospitals increase the number of patients identified for trials and minimise time and staff effort that is required for screening manually.

People will also get access to life-changing treatments that could help them live longer.

VigiLanz and Sharp HealthCare recently collaborated for implementing the solution for an acute cardiac clinical trial.

Leveraging data in Sharp’s electronic health record (EHR), VigiLanz Research automated screening processes and increased the number of patients screened to include all of them in complete units.

This approach increased patient enrollment in the study.

Sharp HealthCare Outcomes Research Institute director of research DeAnn Cary said: “VigiLanz Research has not only improved our team’s efficiency but also has helped us make a difference in patients’ lives.

“With near real-time updates, we can now identify and enroll subjects who may have otherwise been missed.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact